Zimmer price target raised to $113 from $105 at Cantor Cantor increased its price target on Zimmer after the company agreed to buy Biomet. The firm thinks that, beginning in the second year of the deal, Zimmer's accretion guidance could be slightly conservative. It keeps a Buy rating on the stock.
BIOLASE CEO Jeffrey Nugent to step down, Harold Flynn appointed CEO BIOLASE (BIOL) announced that Harold Flynn Jr. will become president and CEO, effective July 13. The current president and CEO Jeffrey Nugent will step down at that time. Since 2007, Flynn has been president of Zimmer Dental, a manufacturer and provider of medical devices for the dental market. Zimmer Dental is a division of Zimmer Holdings (ZMH).